Jeffrey S. Bornstein net worth and biography

Jeffrey Bornstein Biography and Net Worth

Director of AlloVir

Mr. Bornstein serves as a managing partner of Whipstick Ventures and Generation Capital, and was the Chief Financial Officer and Vice Chairman of General Electric until October 2017. Previously, Mr. Bornstein served as a Senior Vice President and Chief Financial Officer of GE Capital. He is a trustee of Northeastern University, and a member of the Board of Directors of buildOn, Inc. Mr. Bornstein obtained his BS degree from Northeastern University.

What is Jeffrey S. Bornstein's net worth?: The estimated net worth of Jeffrey S. Bornstein is at least $765,210.29 as of September 12th, 2024. Mr. Bornstein owns 84,929 shares of AlloVir stock worth more than $765,210 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Bornstein may own. Learn More about Jeffrey S. Bornstein's net worth.
How do I contact Jeffrey S. Bornstein?: The corporate mailing address for Mr. Bornstein and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at ir@allovir.com. Learn More on Jeffrey S. Bornstein's contact information.
Has Jeffrey S. Bornstein been buying or selling shares of AlloVir?: Jeffrey S. Bornstein has not been actively trading shares of AlloVir during the last ninety days. Most recently, on Tuesday, April 26th, Jeffrey S. Bornstein bought 217 shares of AlloVir stock. The stock was acquired at an average cost of $106.72 per share, with a total value of $23,158.24. Following the completion of the transaction, the director now directly owns 1,747 shares of the company's stock, valued at $186,439.84. Learn More on Jeffrey S. Bornstein's trading history.
Who are AlloVir's active insiders?: AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.
Are insiders buying or selling shares of AlloVir?: In the last year, insiders at the sold shares 47 times. They sold a total of 5,878 shares worth more than $90,414.75. The most recent insider tranaction occured on March, 26th when CAO Brett R Hagen sold 907 shares worth more than $8,135.79. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.
Information on this page was last updated on 3/26/2025.

Jeffrey S. Bornstein Insider Trading History at AlloVir

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/26/2022	Buy	217	$106.72	$23,158.24	1,747
2/10/2022	Buy	217	$204.01	$44,270.17

Jeffrey S. Bornstein Buying and Selling Activity at AlloVir

AlloVir Company Overview

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Today's Range

Now: $9.01

$9.01

$9.91

50 Day Range

MA: $9.82

$8.82

$11.47

2 Week Range

Now: $9.01

$7.96

$24.15

Volume

18,903 shs

Average Volume

16,674 shs

Market Capitalization

$45.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63